Recombinant lymphotoxin cDNA and variants
US5824509A · kind A · utility
13Cited by
4References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 19, 1995 |
| Grant date | Oct 20, 1998 |
| Priority date | — |
| Expiry date | May 19, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein enable the economical preparation of compositions containing uniform lymphotoxin polypeptides and variant lymphotoxins having amino acid sequences that differ from those found in nature. The lymphotoxins are purified to a specific activity of 2-10.times.10.sup.7 units/mg of protein by purification using a novel immobilized, lymphotoxin-neutralizing monoclonal antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.